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to harbor secondary mutations in EGFR which may predict both
primary and secondary resistance. The best studied of these is
the T790M mutation which is seen in nearly half of patients with
acquired resistance to drug. Furthermore mutation testing allows
clinicians to base treatment based on the type of mutation. It is
highly likely that not all mutations will be equivalent in predicting
response. Deletions in exon 19 are likely to be more predictive of
response to TKI treatment than point mutations in exon 21. Fur-
thermore there is emerging evidence that mutations in exon 20
might be predictive of primary resistance to EGFR treatment.
Selection of agents based on mutation testing is under review
in the setting of secondary resistance to EGFR-TKI treatment. A
phase II study of dual kinase, irreversible inhibitor HKI-272 is
underway in North America and Europe. In this trial patients
who have progressed after 12 weeks of TKI treatment are treated
with HKI-272 in cohorts based on mutation status. It is highly
likely that several new agents in development will be entered into
similarly designed studies.
EGFR is not the only target where molecular staging will be of
use. Ras is an important target in lung cancer, particularly smo-
ker’s lung cancer. Mutations in K-ras are seen in nearly 30% of
NSCLC patients. While the Ras farnesyl transferase inhibitors
have not proven to be of clinical benefit there are several other
agents that have preclinical activity and will be examined in
patients with ras-mutations. Determination of ras-mutation sta-
tus has been proposed by some to be helpful in predicting resis-
tance to EGFR-TKI so this might have even more relevance in
lung cancer treatment.
Finally gene expression arrays are under intensive investiga-
tion as potentially useful molecular staging tests. Studies are
underway to determine the utility of expression profiling as a
means of determining prognosis in lung cancer. While this tech-
nique is currently limited to fresh tissue if it proves useful it may
become a routine test performed on resected lung cancers to help
prognosticate outcome and to select patients for potential adju-
vant trials.
doi:10.1016/j.ejcsup.2006.04.057
S56. siRNA-TECHNOLOGY ON THE ROAD TO MOLECULAR
THERAPY
Steven Dooley, Patrico Godoy. Center of Molecular Alcohol Research
in Gastroenterology, II. Medical Clinic, University Hospital Mannheim,
University of Heidelberg, Germany.
The possibility to specifically knock down gene expression in a
cellular system is a powerful way to study its function. RNA inter-
ference (RNAi) as molecular mechanism for gene silencing in
mammalian cells has allowed the discovery of several new and
exciting regulatory mechanisms in apoptosis, cell cycle and can-
cer. The technology was recently improved by new delivery meth-
ods allowing both enhanced and long lasting silencing of target
genes, that is, more efficient transfection reagents, and genera-
tion of plasmid and virus based vectors for siRNA delivery. The
possibility of RNAi-scale up for high-throughput (HT) analyses
was used in several genome-wide screens. Thus, HT knock down
for mammalian kinases revealed important new features in the
control of critical cellular steps of endocytosis. The power of these
approaches can be harnessed to delineate complex signal trans-
duction pathways leading to disease. TGF-b is a major cytokine
in liver physiology. It regulates both cell proliferation and apopto-
sis of hepatocytes, and is the main drive of fibrosis, a typical com-
plication of chronic liver diseases. Our goals are to use high
throughput siRNA technologies to discover new and pathobio-
chemically relevant regulatory components of the TGF-b pathway
in liver cells with potential as targets for therapeutic intervention.
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Retroviral gene therapy has been coming of age, reaching unprec-
edented levels of therapeutic efficacy. While the monoallelic inte-
gration of replication-defective vectors was thought to be without
considerable consequences on the host genome, recent reports
on vector integration related genotoxicity in preclinical animal
models have raised concerns on the biosafety of clinically applied
vectors. Possible side effects of vector integration ranged from
immortalization of transduced cells, clonal dominance to inser-
tional oncogenesis. A vector related genotoxicity has occurred
in leukemogenesis in 3 SCID-X1 patients, with remarkable consis-
tency by vector-induced LMO2 oncogene activation, putatively
enhanced by a synergetic effect of the constitutively expressed
vector transgene IL2RG. In the first successful gene therapy trial
of chronic granulomatous disease, we have now observed even
more intensive but thus far non-toxic insertional side effects
resulting in activation of MDS1/EVI1, PRDM16 or SETBP1 5 months
after therapy that produced a 3- to 4-fold expansion of gene-cor-
rected long term myelopoiesis in both treated patients, notably
without signs of leukaemia to date. Prospective monitoring of
vector integration sites in clinical gene therapy studies is feasible,
can detect possible side effects of gene therapy in real-time and
may gain new insights in basic monogenic mechanisms leading
to specific clonal behaviour in vivo.
doi:10.1016/j.ejcsup.2006.04.133
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In 1981 we hypothesized that blockade of the binding site for EGF
and TGF-alpha on EGFR with an antireceptor monoclonal anti-
body (mAb) might be an effective anti-cancer therapy, by inhibit-
ing activation of the receptor tyrosine kinase. Murine mAb 225
inhibited EGFR tyrosine kinase activity, and inhibited tumor cell
growth in cultures and in nude mouse xenografts. C225 (cetuxi-
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